Status:
COMPLETED
Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Parkinson Disease
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this PMS study is the evaluation of depressive symptoms measured with Unified Parkinson's Disease Rating Scale (UPDRS) Part I (mentation, behavior and mood) and with Hospital Anxiety ...
Eligibility Criteria
Inclusion
- Idiopathic PD with or without fluctuations
- Indication for treatment with Pramipexole
- Presence of at least mild depressive symptoms (as judged by the treating physician)
- Ability to reliably complete a self-rating scale (Hospital Anxiety and Depression Scale (HADS))
Exclusion
- Any contraindications according to the Summary of Product Characteristics (SPC), hypersensitivity to pramipexole or to any of the excipients
- Ongoing treatment with pramipexole
Key Trial Info
Start Date :
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
286 Patients enrolled
Trial Details
Trial ID
NCT00651183
End Date
April 1 2008
Last Update
May 20 2014
Active Locations (57)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim Investigational Site
Amstetten, Austria
2
Boehringer Ingelheim Investigational Site
Bad Hall, Austria
3
Boehringer Ingelheim Investigational Site
Bad Ischl, Austria
4
Boehringer Ingelheim Investigational Site
Bad Radkersburg, Austria